TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6802018

Group type: EXPERIMENTAL
Intervention: Combined intravenous administration of 18 mg/h dihydralazine and 0.6 mg/h nitroglycerin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 30476315

Group type: EXPERIMENTAL
Intervention: brief cognitive behavioral therapy (bCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: enhanced usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 0
Study: 30236042

Group type: EXPERIMENTAL
Intervention: Topical sinecatechins (TS) 10% applied twice daily after CO2 laser treatment; 60 subjects in this group.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no treatment); 27 subjects in this group.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Topical sinecatechins (TS) 10% applied twice daily; 60 subjects in this group.
Number of subjects: 87
Study: 28863316

Group type: EXPERIMENTAL
Intervention: Hormonal Contraceptives (HC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No-Hormonal Contraceptives (no-HC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Men
Number of subjects: 130
Study: 26888572

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation with aortic stenosis (AS)
Number of subjects: 14119

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation with mitral regurgitation (MR) or aortic regurgitation (AR)
Number of subjects: 14119

Group type: COMPARATOR
Intervention: No significant valve disease (no SVD)
Number of subjects: 14119

Group type: EXPERIMENTAL
Intervention: Rivaroxaban in patients with MR or AR
Number of subjects: 14119
Study: 24342522

Group type: EXPERIMENTAL
Intervention: lanreotide, 120 mg, subcutaneously every 28 days for 120 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: lanreotide
Number of subjects: 300
Study: 22035883

Group type: EXPERIMENTAL
Intervention: Double-dose methotrexate (50mg/m² intramuscularly on days 0 and 4)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Single-dose methotrexate (50mg/m² intramuscularly on day 0)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Double-dose methotrexate
Number of subjects: 157

Group type: COMPARATOR
Intervention: Single-dose methotrexate
Number of subjects: 157
Study: 20538165

Group type: EXPERIMENTAL
Intervention: HDL selective delipidated plasma infusions
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control plasma apheresis/reinfusions
Number of subjects: 28
Study: 18834244

Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive MOX
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive DOX
Number of subjects: 92

Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 92
Study: 15983685

Group type: EXPERIMENTAL
Intervention: Glutamine treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: No glutamine treatment (Control)
Number of subjects: 48
Study: 11792919

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 ml of 1% lidocaine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (5 ml of 0.9% sodium chloride)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine and Control
Number of subjects: 90
Study: 10619657

Group type: EXPERIMENTAL
Intervention: Scene processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face processing
Number of subjects: 0
Study: 8912502

Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid (GLA) 2.8 gm/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: sunflower seed oil (placebo)
Number of subjects: 56
Study: 1897808

Group type: EXPERIMENTAL
Intervention: Bricanyl Turbuhaler (0.5 mg x 1 terbutaline)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Albuterol metered dose inhaler (0.1 mg x 2 albuterol)
Number of subjects: 16
Study: 6224500

Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 1881

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1881
Study: 31356986

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 146
Study: 30178064

Group type: EXPERIMENTAL
Intervention: Comprehensive residential lead-exposure reduction intervention
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 355
Study: 27405587

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Anxiety Treatment in Schools (CATS)
Number of subjects: 360

Group type: COMPARATOR
Intervention: FRIENDS protocol
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Implementation strategies (train-the-trainer vs. train-the-trainer + ongoing consultation)
Number of subjects: 360
Study: 25370953

Group type: EXPERIMENTAL
Intervention: 100 mg of acotiamide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg of acotiamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22176212

Group type: EXPERIMENTAL
Intervention: Audiovisual aid (AVA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no AVA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 120
Study: 20483046

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 84
Study: 17563154

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CBT plus imipramine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CBT plus placebo
Number of subjects: 91
Study: 16095473

Group type: EXPERIMENTAL
Intervention: Dichotic listening training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study: 11881883

Group type: EXPERIMENTAL
Intervention: Desflurane at fresh gas flows of 3, 1, and 0.5 litre min(‐1)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Halothane at fresh gas flows of 3, 1, and 0.5 litre min(‐1)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Isoflurane and enflurane at fresh gas flows of 0.5 and 3 litre min(‐1)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: More soluble agents (Isoflurane, enflurane)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 302
Study: 10207805

Group type: EXPERIMENTAL
Intervention: Diuretics plus albumin, 12.5 g/day (group B)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Diuretics plus albumin (25 g/week) (group B)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Diuretics (group A)
Number of subjects: 126
Study: 7705006

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (10 pmol min-1 kg-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (10 pmol min-1 kg-1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2650896

Group type: COMPARATOR
Intervention: Group I: 20 ml of lidocaine two per cent with epinephrine via needle at a rate of 5 ml.30 sec‐1 after a 3 ml test dose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group II: 20 ml of lidocaine two per cent with epinephrine in increments of 5 ml injected through a catheter after a 3 ml test dose
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group I
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 971703

Group type: EXPERIMENTAL
Intervention: Cefoxitin (0.5, 1, and 2 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cephalothin (0.5, 1, and 2 g)
Number of subjects: 18
Study: 31543474

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg daily for one week, then 100 mg daily for up to 11 weeks
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 655
Study: 26031901

Group type: EXPERIMENTAL
Intervention: Zileuton treatment
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Montelukast treatment
Number of subjects: 526
Study: 24908956

Group type: EXPERIMENTAL
Intervention: Vazonat (1000 mg/day intravenously for 15 days, then 250 mg 3 times per os for 1 month)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vazonat (1000 mg/day intravenously for 15 days, then 250 mg 3 times per os for 1 month) + Adapto (500 mg twice a day throughout the supervision period)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Basic therapy (control group)
Number of subjects: 92
Study: 23749780

Group type: EXPERIMENTAL
Intervention: Structured exercise programme with motivational techniques
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143
Study: 20217115

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (75 g of glucose 1 hour before exercise)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (fasting, n = 7)
Number of subjects: 15
Study: 18387391

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 37
Study: 16572114

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline albuminuria
Number of subjects: 0
Study: 14985796

Group type: EXPERIMENTAL
Intervention: Power Slot light curing (Reliance Ortho 2000 curing light with Power slot), curing every bracket for 6 seconds
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional light curing (Kulzer light curing machine), curing every bracket for 20 seconds using Quick Cure Composite resin (Reliance Orthodontics)
Number of subjects: 50
Study: 10902827

Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium (40 mg daily)
Number of subjects: 16
Study: 8737216

Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (1500 mg daily for 6 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Diltiazem (180 mg daily for 3 weeks, followed by 360 mg daily for 3 weeks)
Number of subjects: 46
Study: 7840730

Group type: EXPERIMENTAL
Intervention: metoprolol (100 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: nicardipine (90 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: captopril (75 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: chlorthalidone (control group)
Number of subjects: 39
Study: 2900977

Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 15 weeks
Number of subjects: 2482

Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 15 weeks (for babies born to screened women who smoked)
Number of subjects: 2482

Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 15 weeks (for babies born to non-smokers)
Number of subjects: 2482
Study: 31161855

Group type: EXPERIMENTAL
Intervention: Isostretching twice a week for 45 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (waiting list for physical therapy)
Number of subjects: 54
Study: 31596326

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling (FMS) with systemic azithromycin (500 mg/day for three consecutive days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planning (QSRP) with systemic azithromycin (500 mg/day for three consecutive days)
Number of subjects: 34
Study: 28249084

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Heparin plus GPI
Number of subjects: 3602
Study: 28719693

Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D oral supplementation (high-dose group)
Number of subjects: 703

Group type: COMPARATOR
Intervention: 400 IU/d of vitamin D oral supplementation (standard-dose group)
Number of subjects: 703
Study: 23746666

Group type: EXPERIMENTAL
Intervention: Panitumumab combined with cisplatin and fluorouracil
Number of subjects: 657

Group type: COMPARATOR
Intervention: Control group (cisplatin and fluorouracil only)
Number of subjects: 657
Study: 22119973

Group type: EXPERIMENTAL
Intervention: High serum CA-125 levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 30
Study: 19562534

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: General Anesthesia + Epidural (GA+E)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: General Anesthesia + Lumbar Plexus Block (GA+LPB)
Number of subjects: 45
Study: 17553362

Group type: EXPERIMENTAL
Intervention: Mass, selective or opportunistic screening for prostate cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study: 15271714

Group type: EXPERIMENTAL
Intervention: Propofol (n = 6)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thiopental (n = 4)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both Propofol and Thiopental
Number of subjects: 10
Study: 11338290

Group type: EXPERIMENTAL
Intervention: Amino-acid-based formula (AA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Extensively hydrolyzed cow's milk formula (eHF)
Number of subjects: 73
Study: 8780279

Group type: EXPERIMENTAL
Intervention: Patient-controlled intranasal analgesia (PCINA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 50
Study: 1502842

Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine containing B/Yamagata/16/88
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Madin‐Darby canine kidney (MDCK)‐grown virus as an antigen in the haemagglutination inhibition test (HI)
Number of subjects: 104
Study: 6429878

Group type: EXPERIMENTAL
Intervention: Clemastine (0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31299392

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using 5% 5-aminolevulinic acid in gel form, irradiated with a halogen lamp (590-760 nm) for 10 minutes, repeated weekly for 10 weeks.
Number of subjects: 10
Study: 27013028

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard Multimodal Therapy (TRAD)
Number of subjects: 28
Study: 25809913

Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics (Bacillus subtilis and Streptococcus faecium) and mosapride (various doses)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics and mosapride
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics and mosapride (group 4)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics (group 1)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics (group 4)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 23599248

Group type: EXPERIMENTAL
Intervention: Intermittent infusion (every 4 hours from 8:00 to 20:00)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Continuous infusion (24 hours/d)
Number of subjects: 34
Study: 22581391

Group type: EXPERIMENTAL
Intervention: THC (400 μg/kg body weight) with alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol (doses aimed at 0.5 and 0.7 mg/mL) with THC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dräger Drug Test® 5000
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Securetec Drugwipe® 5
Number of subjects: 20
Study: 20043432

Group type: EXPERIMENTAL
Intervention: Postpartum breastfeeding counselling (peer breastfeeding counselling)
Number of subjects: 179

Group type: COMPARATOR
Intervention: No counselling (control group)
Number of subjects: 179
Study: 17695680

Group type: EXPERIMENTAL
Intervention: Prolonged antibiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of prolonged antibiotic therapy and surgery
Number of subjects: 0
Study: 15477122

Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (Sivelestat)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study: 11473855

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg/kg IV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9739379

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (1.2 Gy bid, total dose 74.4 Gy) and simultaneous CDDP chemotherapy (20 mg/m2 daily, 5 days in week 1 and 5)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy and simultaneous CDDP chemotherapy
Number of subjects: 64
Study: 9425393

Group type: EXPERIMENTAL
Intervention: Hexarelin (1 microgram/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hexarelin plus GHRH‐(1‐29)‐NH2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hexarelin (0.5 microgram/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH‐(1‐29)‐NH2 (0.5 microgram/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Withdrawal of SS20 infusion
Number of subjects: 12
Study: 2523322

Group type: EXPERIMENTAL
Intervention: 100 mg NET injectable microspheres
Number of subjects: 131

Group type: COMPARATOR
Intervention: 65 mg NET injectable microspheres
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both doses (65 mg and 100 mg)
Number of subjects: 131
Study: 333492

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30614767

Group type: EXPERIMENTAL
Intervention: Fine tube bundles (FTBs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional drainage tube
Number of subjects: 60
Study: 29266892

Group type: EXPERIMENTAL
Intervention: Audiovisual psychoprophylaxis (video watched before admission)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no audiovisual psychoprophylaxis)
Number of subjects: 100
Study: 26212230

Group type: EXPERIMENTAL
Intervention: Home set-up for unattended home-based polysomnography (H-PSG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sleep laboratory set-up for unattended home-based polysomnography (H-PSG)
Number of subjects: 102
Study: 23790553

Group type: EXPERIMENTAL
Intervention: Extra-thin wall pen needles (XTW PNs)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Current pen needles (usual PNs)
Number of subjects: 216
Study: 21808759

Group type: EXPERIMENTAL
Intervention: VN membrane (new cross-linked collagen membrane)
Number of subjects: 16

Group type: COMPARATOR
Intervention: BG membrane (native collagen membrane)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: VN membrane
Number of subjects: 16

Group type: COMPARATOR
Intervention: BG membrane
Number of subjects: 16
Study: 19596188

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily via metered-dose inhaler (CIC160)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciclesonide 160 microg once daily via AeroChamber Plus (CIC160P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciclesonide 160 microg once daily via AeroChamber MAX (CIC160M)
Number of subjects: 0
Study: 16458625

Group type: EXPERIMENTAL
Intervention: Expanded medical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 100
Study: 15080829

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus and D. farinae 50/50 allergen extract for 2 years
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11418492

Group type: EXPERIMENTAL
Intervention: Electric taste stimuli applied to the right side of the tongue
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Electric taste stimuli applied to the left side of the tongue
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Electric taste stimuli
Number of subjects: 11
Study: 9241097

Group type: EXPERIMENTAL
Intervention: Adrenomedullin at 30 pmol min(‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CGRP at 30 pmol min(‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Adrenomedullin at 10 pmol min(‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CGRP at 10 pmol min(‐1)
Number of subjects: 16
Study: 8032063

Group type: EXPERIMENTAL
Intervention: HT-LVH
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: HT-LVH with ST segment depression
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ECG-LVH in terms of voltage
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Plasma cholesterol levels
Number of subjects: 126
Study: 3108045

Group type: EXPERIMENTAL
Intervention: Combination clomiphene/hMG
Number of subjects: 126

Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Laparoscopic punctures
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ultrasonically guided punctures
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ultrasonically guided punctures with clomiphene/hMG
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ultrasonically guided punctures with hMG alone
Number of subjects: 126
Study: 30377402

Group type: EXPERIMENTAL
Intervention: Injected with levobupivacaine
Number of subjects: 294

Group type: COMPARATOR
Intervention: Injected with saline (Control)
Number of subjects: 294
Study: 26604272

Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin and metronidazole during the first, nonsurgical phase of periodontal therapy (phase 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adjunctive antibiotics during the first phase
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group receiving antibiotics during the second, surgical phase (phase 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adjunctive antibiotics during the second phase
Number of subjects: 80
Study: 25808531

Group type: EXPERIMENTAL
Intervention: Self-reported knee instability group
Number of subjects: 53
Study: 22454003

Group type: EXPERIMENTAL
Intervention: Flexible(MIB) regimen (24-120 days' active hormonal intake with 4-day tablet-free intervals)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Conventional regimen (24 days' active hormonal intake followed by a 4-day hormone-free interval)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Fixed extended regimen (120 days' uninterrupted active hormonal intake followed by a 4-day tablet-free interval)
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Flexible(MIB) regimen
Number of subjects: 1067
Study: 20430775

Group type: EXPERIMENTAL
Intervention: Preoperative lymphoscintigraphy
Number of subjects: 565

Group type: COMPARATOR
Intervention: No preoperative lymphoscintigraphy
Number of subjects: 565